SecBot SecBot
PRESS-RELEASE ·Filed Aug 10, 2026

APGE

Apogee Therapeutics
BULLISH
Impact 8/10
Horizonimmediate Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The stock is trading near the $135.11 acquisition price, leaving limited upside but a low-risk arbitrage for deal completion. Monitor shareholder vote and regulatory approvals; any deal termination risk would cause steep downside. The Phase 2 zumilokibart data supports the acquisition rationale but is now academic given the fixed cash exit.

DirectionBullish
Confidencehigh
Horizonimmediate

Drugs in focus

APGE drug pipeline →

zumilokibart

◆ Mixed Named in this press release
Impact
Phase
Phase 2 complete (positive); Phase 3 planned/initiating 2H 2026
Time to market
Phase 3 initiation guided to 2H 2026 with a company-flagged potential 2029 commercial launch in atopic dermatitis — roughly 3 years from now, assuming Phase 3 success and a standard filing/PDUFA path.
Next catalyst
None dated

What to watchFor APGE holders, the drug's upside is essentially monetized, the stock trades ~0.7% below the $135.11 all-cash offer, so the remaining question is simply whether the AbbVie deal closes in Q3 2026 (mean analyst target $130.53 vs. price ~$134 reflects the capped upside). For AbbVie investors, zumilokibart is a 2030s thesis: watch Phase 3 initiation in atopic dermatitis (guided 2H 2026), interim data from the head-to-head versus Dupixent (2H 2026), and the ~$0.14 FY2026 EPS dilution the deal carries, the Phase 3 readouts that could validate the ~$10.9B price tag are years away.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$134.65
T+0 close · Aug 10, 2026 · via day close
Latest settled
−0.04%
T+5 · $134.59
Vs SPY
+0.00%
α at T+5
Next horizon
T+20
due 2mo ago
  1. T+0 · Aug 10 $134.65entry
  2. T+1 · 3mo ago +0.03%α +0.35% · $134.69
  3. T+5 · 3mo ago −0.04%α +0.00% · $134.59
  4. T+20 · due 2mo ago Pending
  5. T+60 · due 14d ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics reported Q2 2026 results but the quarter's significance is completely overshadowed by AbbVie's pending acquisition of Apogee for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion. The transaction, expected to close in Q3 2026, provides a clear exit value for shareholders. The quarterly financials show a pre-revenue clinical-stage biotech with net loss of $85.9M and cash of $1.3B, which are immaterial given the acquisition premium.

Key Facts

  • AbbVie to acquire Apogee for $135.11 per share in cash, total equity value ~$10.9B
  • Transaction expected to close in Q3 2026, subject to shareholder and regulatory approvals
  • Positive Phase 2 APEX Part B results for zumilokibart in atopic dermatitis met all endpoints
  • Cash position of $1.3B as of June 30, 2026, up from $621.2M a year ago
  • Net loss of $85.9M for Q2 2026 vs $66.1M in Q2 2025
  • Strategic financing collaboration with Blackstone Life Sciences for up to $1.3B in non-dilutive capital

Financial Impact

Acquisition at $135.11/share implies ~7% premium over current market cap of $10.2B, with shareholders receiving cash exit

share priceequity value

Risk Factors

  • Deal fails to close due to regulatory or shareholder rejection
  • AbbVie terminates agreement under material adverse change clause
  • Competing bid or antitrust challenges delay or block transaction

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
33% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3341678

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Viewing Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (11h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026